Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: XNCR 4 – 2 ENTA Matrix Metrics: XNCR 6 – 4 ENTA

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -90.0% operating margin) and revenue trajectory (+454.9% vs. -21.6% YoY).
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs ENTA
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (XNCR 4 – 2 ENTA)

Columns: Metric · XNCR · ENTA
1. Valuation Multiples ENTA
Forward P/E 68.0x 44.0x
Trailing P/E 68.0x 44.0x
PEG Ratio N/M N/M
EV / Revenue 14.8x 5.3x
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) $200M $65M
Market Cap $2.9B $326.2M
3. Profitability & Quality XNCR
Gross Margin -42.5% 100.0%
Operating Margin -72.7% -90.0%
Net Profit Margin -58.8% -96.9%
Return on Equity (ROE) -19.9% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$176M -$37M
Cash Flow Margin -88.0% -56.6%
Net Cash / Leverage $101M Net Debt (0.29x D/E) $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 79.0% (10th %ile) 78.7% (11th %ile)
Put/Call OI Skew N/A 0.31x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (6) vs ENTA (4)
Institutional Metric XNCR ENTA Criterion Row Edge
Market Capitalization
Scale
$2.9B $326.2M Larger Scale XNCR
Trailing P/E Ratio
Valuation
68.0x 44.0x Lower Multiple ENTA
Forward P/E Ratio
Valuation
68.0x 44.0x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
+454.9% -21.6% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% -90.0% Higher Margin XNCR
Net Profit Margin
Profitability
-58.8% -96.9% Higher Margin XNCR
Return on Equity (ROE)
Capital Efficiency
-19.9% -70.1% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 10% ($10–$17) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 0.89β · 58% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 46.2 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$200M $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev N/M PEG · 5.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +58.63 pp
XNCR: +55.84% · ENTA: -2.79%
3M Horizon XNCR +59.01 pp
XNCR: +40.14% · ENTA: -18.87%
6M Horizon XNCR +241.75 pp
XNCR: +221.97% · ENTA: -19.78%
1Y Horizon XNCR +162.48 pp
XNCR: +154.54% · ENTA: -7.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period XNCR Revenue ENTA Revenue XNCR Op. Margin ENTA Op. Margin Margin Leader
FY2018 $40M $210M -195.5% 42.7% ENTA
FY2019 $160M $210M 8.8% 17.9% ENTA
FY2020 $120M $120M -62.6% -34.0% ENTA
FY2021 $280M $100M 15.9% -112.9% XNCR
FY2022 $160M $90M -50.1% -143.7% XNCR
FY2023 $170M $80M -75.8% -173.2% XNCR
FY2024 $110M $70M -161.5% -179.9% XNCR
FY2025 $130M $70M -141.4% -130.7% ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -90.0% operating margin) and revenue trajectory (+454.9% vs. -21.6% YoY). Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

ENTA screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.